POPULARITY
34 episodes with bcl
31 episodes with bcl
65 episodes with bcl
23 episodes with bcl
24 episodes with bcl
25 episodes with bcl
24 episodes with bcl
19 episodes with bcl
18 episodes with bcl
25 episodes with bcl
13 episodes with bcl
9 episodes with bcl
6 episodes with bcl
13 episodes with bcl
7 episodes with bcl
120 episodes with bcl
6 episodes with bcl
4 episodes with bcl
4 episodes with bcl
2 episodes with bcl
5 episodes with bcl
6 episodes with bcl
3 episodes with bcl
36 episodes with bcl
4 episodes with bcl
4 episodes with bcl
3 episodes with bcl
2 episodes with bcl
2 episodes with bcl
4 episodes with bcl
19 episodes with bcl
2 episodes with bcl
2 episodes with bcl
11 episodes with bcl
2 episodes with bcl
10 episodes with bcl
2 episodes with bcl
6 episodes with bcl
5 episodes with bcl
4 episodes with bcl
4 episodes with bcl
4 episodes with bcl
3 episodes with bcl
3 episodes with bcl
3 episodes with bcl
Empieza un nuevo curso en el que me comprometo a traerles más baloncesto, si cabe, que en los años anteriores. En este espacio hablaremos durante los próximos meses de toda la actualidad del mundo de la canasta, de la Liga Endesa, de la Liga femenina Endesa, del U22, de Primera FEB, de las competiciones internacionales y, por su puesto, de los equipos de la Región de Murcia. El nuevo proyecto del UCAM Murcia está muy renovado con respecto al curso anterior. Alejandro Gómez y Sito Alonso han conformado una plantilla con siete caras nuevas que después lo analizaremos en la tertulia (donde, por cierto, les adelanto que también habrá caras nuevas. La última hora del equipo es que hoy viernes jugará su primer amistoso de la pretemporada, será en el Palacio a puerta cerrada ante el Covirán Granada. El domingo disputará su segundo duelo y ese sí podremos verlo. Será en Yecla, ante el Valencia Basket, a partir de las 13h y la entrada será gratuita. Hay que recordar que los de Sito Alonso necesitan coger rápidamente el ritmo de competición porque el día 20 de este mes inician la fase previa para estar en BCL la próxima temporada. Analizamos la actualidad del equipo universitario en la tertulia con Jaime Nadal, Emilio Sánchez-Bolea y Laura Fernández. En el apartado nacional, repasaremos con la periodista Noelia Gómez el papel de la selección española en el Eurobasket y la última hora de la Liga Endesa.
If you have been listening to my podcast for a while, you will know how much I value my involvement with STEP (the Society of Trust and Estate Practitioners). It is not just about the TEP designation. What I love most are the connections, the learning, and the high-quality professional development that STEP provides. Honestly, it is some of the best CPD I get all year! So, I am taking a quick detour from regular podcast programming to share with you the exciting lineup of events we have planned for our STEP Saskatchewan Branch! Attendance at STEP events is open to non-members and members. We are excited to launch the 2025-2026 Season for STEP Saskatchewan, and in this episode, I walk you through what is coming up this year! All sessions are available in person or on demand - and the topics for this season have broad applicability outside of just Saskatchewan practitioners. Here is the scoop:September 15, 2025 - We are kicking off the season with a BIG celebration (STEP Saskatchewan is the first Chapter in Canada to achieve full branch status!)October 8, 2025 – Tax Update: Top Estate and Trust Issues (with special guest, Kenneth Keung, CPA, CA, CPA (CO, USA), CFP, MTAX, LLB, TEP, Vancouver: Doane Grant Thornton LLP)November 5, 2025 – Death of a Property Owner - Planning with Interests in Real Estate (with special guests, Tannis Dawson CPA, CA, CFP, RRC, FEA, TEP, Winnipeg: TD Wealth and Krista Evanisky, JD, TEP, Saskatoon: Clarity Law)April 8, 2026 – A Practitioner's Guide to the Trust Life Cycle: Tax and Best Practices (with special guest, Troy McEachren, BCL, LLB, TEP, Montreal: Miller Thomson LLP)May 6, 2026 – US Cross Border Properties and Estates (with special guest, Mariska Loeppky, CPA, CA, CFP, TEP, Winnipeg: IG Private Wealth Management)RESOURCES DISCUSSED ON THIS EPISODE:www.step.caSTEP Saskatchewan RegistrationOur fabulous speakers:Kenneth KeungTannis DawsonKrista EvaniskyTroy McEachernMariska Loeppky HERE ARE SOME OTHER WAYS TO CONNECT WITH ME:My website! Email: thetaxchickpodcast@gmail.com@tax.chick (IG) LinkedInBe a "Tax Chick VIP"
In this episode of Cutaneous Miscellaneous, host Nicholas Brownstone, MD, is joined by Ryan Svoboda, MD, for an in-depth review of cutaneous lymphomas. They begin with a boards review of the four primary cutaneous B-cell lymphomas—two indolent (follicle center, marginal zone) and two aggressive (diffuse large B-cell, intravascular B-cell). The discussion covers prognostic differences, biopsy strategies, key immunostains, helpful mnemonics for BCL markers, and notable associations such as Borrelia infection. In the main segment, the focus shifts to cutaneous T-cell lymphomas, particularly mycosis fungoides. Dr Svoboda shares diagnostic challenges, strategies to improve biopsy yield, and a practical scoring algorithm to interpret inconclusive pathology reports. They also review tips for diagnosing Sézary syndrome and highlight relevant NCCN guidelines. Tune in to the full episode for high-yield insights on recognizing, diagnosing, and managing both B-cell and T-cell cutaneous lymphomas in clinical practice.
Fertility Docs Uncensored is hosted by Dr. Carrie Bedient from the Fertility Center of Las Vegas, Dr. Susan Hudson from Texas Fertility Center, and Dr. Abby Eblen from Nashville Fertility Center. In this listener Q&A episode, the docs take on an emotionally tough but important topic: what to do after a failed IVF cycle. They dive deep into strategies to improve egg numbers, enhance embryo quality, and increase the chances of implantation success in future cycles. The conversation includes how a hysteroscopy can help detect fibroids or polyps that might create inflammation in the uterus, the impact of bacterial inflammation, and diagnostic tools like the ReceptivaDx test, which checks for the inflammatory marker BCL-6. BCL-6 may be linked with inflammation from endometriosis. The docs also touch on evaluating sperm DNA fragmentation and exploring the uterine microbiome. For those with positive signs of inflammation, treatment options such as Lupron or even laparoscopy to remove endometriosis are discussed. And don't miss the discussion on progesterone timing for frozen embryo transfer cycles—why the number of hours of exposure to progesterone can be critical for opening the window of implantation at just the right time. Tune in for a practical, science-based guide to navigating next steps after IVF doesn't go as planned. This episode was sponsored by ReceptivaDx.
Jim O'Callaghan is the Minister for Justice, Home Affairs and Migration. He was elected to Dáil Éireann for the constituency of Dublin Bay South in the general elections of 2016, 2020 and 2024. Previously, he had been a councillor on Dublin City Council. He has served as a member and Chairman of the Oireachtas Committee on Justice and was also a member of the Oireachtas Finance and Education Committees. He has been the Fianna Fáil spokesperson on Justice since 2016. He is a law graduate (BCL) of University College Dublin and attained a Master of Law (LLM) degree and a Master in Philosophy (M.Phil) degree in Criminology from the University of Cambridge. He also holds a Barrister-at-Law degree from the King's Inns and has been a Senior Counsel since 2008.
Ibon Navarro:Ibon Navarro is a highly accomplished Head Coach in Europe and today he came to our summit in Vilnius to talk about the culture he created in Malaga, Spain! The two time King's Cup & back to back BCL championship coach has a lot of experience already and today we spoke about his practice habits as well as the habits he expects from his players. How the team culture is supposed to impact and help new players adapt easier and much more.Today's Topics:0:00 Intro2:10 Sleep & Off Season5:00 BCL Back to back process12:00 Alex Ferguson Quote14:20 James Clear Quote / Habits19:30 Information gathering / Recruitment22:50 Impact of culture25:15 Unconventional Practices32:00 Lessons from the past35:30 Substitution pattern42:00 Q&AFind Ibon Navarro here: IG: https://www.instagram.com/ibon.navarro76/ FB: https://www.facebook.com/ibontxun B8 Summit Website:www.b8summit.comThe Benas Podcast:www.bmatke.com #b8summit #basketballsummit #Vilnius #Lithuania #Basketball #podcast #conference #Growth #learning #conversations #Unicaja #Malaga #BCL #Champion
L'été arrive et l'équipe vous propose un nouveau format : celui de la Tier List EuroLeague ! Romain et Lucas vont tenter de classer les joueurs en fonction de leur saison régulière, et de ne retenir que l'élite du basketball européen. Alors, qui finira dans les plus hauts rangs ?-------------------------------------------- ABONNEZ-VOUS
Semana de noticias en el UCAM Murcia. El club universitario hizo oficial el miércoles que Tonik Nakic será su nuevo ala-pívot la próxima temporada. El croata de 26 años y 2,01m de altura ha estado en el Río Breogán las últimas tres temporadas, es un jugador capaz de abrir el campo (ha promediado cerca del 46% desde el triple) y es un jugador muy luchador. Nakic firma por el UCAM Murcia para un año, con opción a otro. Además, los de Sito Alonso ya saben que tendrán que jugar la fase previa de la BCL, un torneo que se disputará del 23 al 28 de septiembre en una sede todavía por confirmar. De los 24 equipos que disputen esta ronda clasificatoria, sólo tres accederán a la fase regular de la Basketball Champions League. Hablamos de todo ello en la tertulia, con Andrés Miso y Emilio Sánchez-Bolea. Por último, Chema de Lucas nos traerá la última hora del mercado en la Liga Endesa.
Los titulares de la semana en 2Playbook.com junto a Álvaro Carretero y Patricia López. Hoy analizamos la asistencia de todas las grandes ligas estadounidenses, patrocinios del Atleti y Juventus, el cambio a la BCL de Gran Canaria y Joventut, el acuerdo del Ayuntamiento con Marbella FC y las aficionadas del fútbol femenino. Además, suscríbete a 2Playbook y llévate el informe LaLiga Commercia Report con un 20% DE DESCUENTO. ¡Y recuerda que tienes un 50% de descuento si eres estudiante! ¿Quieres más podcast de la industria del deporte? Apunta: SPORTS, INSIDE by 2Playbook 2Playbook Breaking News PRO Media & Content PRO Women in Sport PRO Fitness¡Próximos Eventos!PRO Sportstech, 19 de junio en MadridGracias!Contacto, sugerencias y feedback: podcast@2playbook.com
John N. Allan, MD and Andrew H. Lipsky, MD discuss the evolution of CLL therapy and the power of doublet and triplet regimens, exploring combinations including BTK inhibitors with BCL-2 inhibitors and anti-CD20 monoclonal antibodies.
Ça y est, la saison EuroLeague est terminée ! Le Fenerbahçe a été sacré champion face à l'AS Monaco. Une finale entre le club turc et la Roca Team qui aura été une véritable surprise à Abu Dhabi. L'occasion pour Romain et Lucas de revenir sur la rencontre, ce qui a marché et raté pour les deux équipes, et pourquoi pas aussi se projeter sur l'avenir, les dynamiques des deux équipes et l'intersaison qui approche... Enjoy-------------------------------------------- ABONNEZ-VOUS
國泰世華 CUBE Podcast 節目「解鎖從容理財」由主持人小詹與證券投資分析師薯哥分享財經情勢與理財小故事的與你一起創造「從容投資、品味理財」的態度生活。立即收聽 ➡️ https://fstry.pse.is/7l4x2c —— 以上為 KKBOX 與 Firstory Podcast 廣告 —— 錄音當下PLG總冠軍賽第六戰落幕，領航猿在背水一戰中成功扳回一城，將系列賽逼進PLG史上首場Game 7！然而，當我們的目光還停留在PLG的激烈對決時，另一邊TPBL的季後賽舞台已悄然搭建完成。這場全新賽事的王者之爭，新聯盟的首個總冠軍究竟會花落誰家？ 本週，小人物上籃誠邀全家海神助教Sean，為大家帶來最專業的TPBL季後挑戰賽解析！Sean將為我們深度剖析戰神與雲豹的攻防特色，兩隊的優勢與短板又會如何影響比賽走向？這次的節目，絕對是所有台籃迷不容錯過的戰術盛宴！ 除了賽事分析，我們還準備了一些「殘酷數據」。一位熱心的小人物提供了今年各隊進場人數的詳細數據，與去年相比，數據的變化讓人驚訝：誰的進場人數暴跌？又是誰逆勢上漲？哪支球隊的公關票派得最凶？誰的票房數據最真實？這些問題，我們將用放大鏡逐一檢視，帶你看清台籃市場的真實面貌。 另外，最近有粉絲留言抱怨我們沒有針對PLG總決賽每場比賽進行分析。在這裡，我們要鄭重澄清：我們有做啦！只要加入我們的小人物上籃會員，就能聽到Roy又哭又笑的情緒起伏、小枚一針見血的評論，以及Kong專業同時一直挖苦Roy的賽事分析。想要掌握台籃季後賽的每場戰況，現在就訂閱小人物上籃會員吧！ 台籃的季後賽熱潮才剛剛開始，無論是PLG的Game 7還是TPBL的挑戰賽，每一場比賽都值得我們全情投入。快到各大podcast平台搜尋小人物上籃，持續鎖定霹靂鍵盤！ 成為
Valencia Basket sigue en pleno proceso de análisis, tratando de tomar la decisión correcta respecto a la competición europea que jugará la próxima temporada. La Cadena SER viene siguiendo el asunto desde hace meses y avisando de la problemática. Para jugar Euroliga hay que acatar normas leoninas. Un canon de dos millones anuales (dinero que los clubes propietarios utilizan para pagar a jugadores con los que ganar a equipos no propietarios como Valencia Basket) y además renunciar al reparto de beneficios. El asunto contiene la paradoja de muchos temas en La Fonteta: se va a construir un pabellón de 300 millones pero en el club dudan a la hora de pagar 6 en tres temporadas. Dicho esto, como cada uno hacer lo que quiere con su dinero, sería lógico que Valencia optara por la BCL. Una competición peor, pero que no exige el pago de ese canon tan alto. Ahora bien, si la elección es finalmente la BCL, hay que reconsiderar el precio de los abonos. No puede pagarse a precio de Filarmónica de Viena una verbena de la Orquesta Expresiones.
Le Final Four c'est cette semaine !L'EuroLeague va rendre son verdict et pour connaître le futur champion d'Europe rien de mieux que de jouer sa fin de saison à... Abu Dhabi.Monaco, l'Olympiacos, le Panathinaïkos et le Fenerbahçe. Voici les prétendants au titre après des semaines de compétition où tous les matchs comptent.Qui prendra la place sur le trône dimanche ?-------------------------------------------- ABONNEZ-VOUS
El UCAM Murcia logró el pasado domingo una victoria fundamental contra el Baxi Manresa para seguir con alguna opción viva de poder entrar en el play off. Es muy complicado porque no depende de sí mismo ya que el D. Gran Canaria ganó al H.Lleida en el partido aplazado el otro día y ha provocado que, debido a los ‘averages', los de Sito Alonso pueden quedarse fuera de la lucha por el título incluso ganando las tres jornadas que quedan. Pero hay que ir a ganarlas porque en juego también está un billete para Europa. En ese sentido, ante el Baxi Manresa, que es un rival directo en la pelea por una plaza para las competiciones continentales, se superó el average. Ganando un partido más que ellos, se les adelantará en la clasificación.Este fin de semana toca ir a Málaga, una pista que trae los mejores recuerdos del año pasado. Enfrente espera un equipazo como es Unicaja, que acaba de ganar la BCL (su cuarto título esta temporada). Hablamos de ello con nuestro protagonista de la semana, Rodions Kurucs. El jugador letón repasa en La Pizarra cómo está siendo la temporada y nos habla de su futuro más inmediato.
Estamos inmersos en las semifinales de cada conferencia de la NBA y nos está dando para mucho análisis. Los Celtics están también contra las cuerdas (1-2 en el momento de grabar el programa) y Denver dando la cara ante OKC. Todo esto, con mucho análisis de baloncesto europeo, los títulos de Unicaja en la BCL y de Valencia Basket en Liga Femenina Endesa. Traemos muchísimo baloncesto en este capítulo, no te lo puedes perder.
El palmarés del Unicaja de Málaga desde 2023 es inmejorable.2 Copas del Rey, 2 Basketball Champions League, una Supercopa Endesa y una FIBA Intercontinental CupLos de Ibon Navarro sumaron este domingo un título más a sus vitrinas al ganar al Galatasaray en la Final Four de la BCL y se coronan como el segundo equipo capaz de vencer en temporadas consecutivasEn el programa de hoy hablamos del éxito del Unicaja, de cómo ha sido su año en la BCL y lo que les queda por delanteEscucha este programa cada mañana en nuestro canal de YouTube o bien en plataformas de podcastGIGANTES DAILY es un programa de Gigantes Podcast en el que tendrás cada mañana la información que necesitas de NBA, Euroliga, ACB, FIBA, femenino y más.Dale a seguir y cada mañana, de lunes a viernes, tendrás un tema clave que va a marcar ese día en el mundo del baloncesto. Todo ello de la mano de Gigantes del Basket, el único medio profesional en España que lleva desde 1985 centrándose en exclusiva en el baloncesto. Más en Gigantes.com y nuestras redes socialesContacto: redaccion@gigantes.com
(0:25) Φάιναλ Φορ BCL(9:20) Tα καλύτερα NBA Playoffs των τελευταίων χρόνων(15:48) Βοστώνη – Νέα Υόρκη(26:49) Κλίβελαντ – Ιντιάνα(32:41) Μινεσότα – Γκόλντεν Στέιτ(41:42) Οκλαχόμα - Ντένβερ(56:40) Βραβεία ΝΒΑ Hosted on Acast. See acast.com/privacy for more information.
Featuring perspectives from Dr Jennifer R Brown and Prof Paolo Ghia, including the following topics: Introduction: The Chronic Lymphocytic Leukemia (CLL) Experience — 2000 to 2025 (0:00) Current Therapy Options with Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (9:42) Role of Venetoclax in the Treatment of CLL (26:52) AMPLIFY Trial and Other Novel BTK Inhibitor and Bcl-2 Inhibitor Combination Strategies (32:29) Noncovalent BTK Inhibitor Pirtobrutinib (46:47) CAR T-Cell Therapy; Novel Agents (56:12) CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Role of Covalent Bruton Tyrosine Kinase Inhibitors and Bcl-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL) — Paolo Ghia, MD, PhD CME information and select publications
In Part 2 of this candid global conversation, Karl Tabbakh returns to The Business of Doing Business to pull back the curtain on the economic uncertainty that's gripping both Canada and the U.S.—and what business leaders need to do about it.Dwayne and Karl dissect the real cost of tariffs, the psychological divide between the “haves” and “have nots,” and what a future recession could mean for Canadian competitiveness. They challenge leaders to rethink productivity, wealth distribution, and their own growth mindset in a time of instability.From political coalitions to personal responsibility, Karl doesn't hold back. If you're in business today, this episode is your compass in the chaos.Timestamps[00:01:00] – The danger of coalitions and the question of democratic representation[00:04:30] – Program creation vs. program funding: Canada's economic blind spot[00:08:30] – Do we have the GDP to fund the lifestyle we promise?[00:10:00] – Why Canada's mindset around growth is dangerously passive[00:13:30] – Who really pays the tariffs—and why they're hidden taxes[00:17:30] – Are tariffs a strategy or political theatre? Dissecting Trump's leverage[00:24:00] – The “Somewheres” vs. “Nowheres”: Stephen Harper's cultural divide explained[00:27:00] – The information echo chamber: Why we don't see disruption coming[00:29:00] – Education, taxation, and why we must fix the divide[00:36:00] – Capitalism's existential threat: What happens when the system loses balance[00:43:30] – CEO pay, productivity, and compensation in a modern economy[00:48:00] – Catching a falling knife: Should you invest in uncertain times?[00:52:00] – When clarity returns, capital will too: Preparing for the rebound[00:57:00] – The world is better than you think—but you have to choose that lens[00:59:00] – Final message: Educate yourself. Lead with purpose. Elevate others.About Karl TabbakhKarl Tabbakh is a lawyer, a business leader and a strategic advisor with over 20 years of international business experience. Karl's expertise is sought after to advise corporations, directors and business executives on a range of strategic issues and transactions both domestically and globally. He is a partner at McCarthy Tétrault LLP with a focus on M&A and private equity and serves on the firm's Senior Leadership Team as National Leader, Markets and International Business. He was appointed by the Government of Canada as Chairman of Invest in Canada, Canada's agency responsible for promoting, attracting and facilitating global foreign direct investments into Canada. He previously served as Chair of the Canadian Chamber of Commerce and was on the Board of directors of the Canada Arab Business Council. Karl is a regular speaker on matters of governance, global investment and mergers and acquisitions. In addition to his career in Canada, Karl spent eight years in the Middle East and four years in London, UK, where he developed a solid international network and gained an understanding of international business and investments. An active community leader, Karl supports and leverages his network to benefit many non-profit and local community service organizations, including as member of the Centraide/United Way campaign. Born in Syria, Karl immigrated with his parents to Canada at age 10. He holds an LLB from Osgoode Hall Law School in Toronto, a BCL from the Université de Montréal and a B.Comm from Université Laval in Québec City. Karl is fluent in French, English, and Arabic.Notable Quotes“Imposing a tariff isn't tax revenue....
El UCAM Murcia sigue sin ganar en casa y ya van casi tres meses en Liga Endesa. El equipo universitario cayó el pasado fin de semana ante el Baskonia (82-91) y suma ya nueve derrotas en competición doméstica ante su afición. Es precisamente en su feudo donde se están escapando los objetivos esta temporada, como la Copa del Rey, el billete para el play off de BCL y veremos si también el play off. En medio de estos resultados, esta semana conocíamos la noticia de que Sito Alonso será el nuevo seleccionador de Letonia a partir de septiembre, después del Eurobasket. Un cargo que no afecta en nada, porque son compatibles, con el UCAM Murcia, donde seguirá la próxima temporada ya que tiene contrato garantizado. Analizamos la actualidad del equipo en la tertulia con Andrés Miso y Laura Fernández. También repasamos los resultados del resto de los equipos de la Región de Murcia: Hozono Global Jairis, el Odilo FC Cartagena y La Salud de Archena.
In today's episode, we had the pleasure of speaking with Nicole Lamanna, MD, about patient selection considerations for the use of pirtobrutinib (Jaypirca) in the management of chronic lymphocytic leukemia (CLL). Dr Lamanna is a hematologic oncologist at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center in New York, New York. In our exclusive interview, Dr Lamanna discussed how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in patients with CLL. She also highlighted important clinical features that guide the use of noncovalent BTK inhibitors—including sequencing strategies following covalent BTK and BCL-2 inhibitors, and emphasized the importance of balancing treatment efficacy with tolerability to optimize long-term disease management in CLL.
In one of the most urgent and eye-opening conversation, Dwayne sits down with Karl Tabbakh—top Canadian business strategist, international dealmaker, and former chair of the Canadian Chamber of Commerce—to unpack the global forces redefining the rules of business, politics, and leadership.Together, they explore what rising geopolitical tension, fractured trade alliances, and shifting world orders mean for entrepreneurs, CEOs, and decision-makers across North America. With experience advising on multi-billion-dollar cross-border transactions and leading strategic investments in Canada and the Middle East, Karl offers a rare lens into how to stay sharp—and sane—in chaotic times.This is part one of a two-part conversation filled with powerful insights on resilience, globalism, and the responsibilities of leadership in the modern era.Timestamps[00:02:45] – Why Karl was the first person Dwayne thought of for this global conversation[00:05:20] – Karl's career snapshot: from billion-dollar deals to chairing Invest in Canada[00:09:45] – A five-year vision framework for career growth and avoiding professional stagnation[00:13:00] – Why global exposure isn't just travel—it's transformational for decision-making[00:17:30] – The danger of only seeing the world through a North American lens[00:21:00] – Are we ignoring the signs of World War III? The breakdown of the post-WWII order[00:25:30] – What the markets are really saying about uncertainty and leadership[00:33:45] – Are nations acting out of fear, or a thirst for certainty?[00:40:00] – Why Canada must rethink its overreliance on one trade partner[00:52:00] – The hard truth about energy, natural gas, and global climate equity[01:03:00] – The upcoming Canadian election: What voters need to be asking[01:11:00] – Vision, will, and resources: Three pillars for Canada's next leader[01:15:00] – Final thoughts: Canada's opportunity to punch above its weight againAbout KarlKarl Tabbakh is a lawyer, a business leader and a strategic advisor with over 20 years of international business experience. Karl's expertise is sought after to advise corporations, directors and business executives on a range of strategic issues and transactions both domestically and globally. He is a partner at McCarthy Tétrault LLP with a focus on M&A and private equity and serves on the firm's Senior Leadership Team as National Leader, Markets and International Business. He was appointed by the Government of Canada as Chairman of Invest in Canada, Canada's agency responsible for promoting, attracting and facilitating global foreign direct investments into Canada. He previously served as Chair of the Canadian Chamber of Commerce and was on the Board of directors of the Canada Arab Business Council. Karl is a regular speaker on matters of governance, global investment and mergers and acquisitions. In addition to his career in Canada, Karl spent eight years in the Middle East and four years in London, UK, where he developed a solid international network and gained an understanding of international business and investments. An active community leader, Karl supports and leverages his network to benefit many non-profit and local community service organizations, including as member of the Centraide/United Way campaign. Born in Syria, Karl immigrated with his parents to Canada at age 10. He holds an LLB from Osgoode Hall Law School in Toronto, a BCL from the Université de Montréal and a B.Comm from Université Laval in Québec City. Karl is fluent in French, English, and Arabic.Notable Quotes“If World War III...
The offseason is nearly over so that means a visit from Kevin Tuve for some rock talk. Daryl Thompson's Blue Crabs tenure is over and so is the Cougars run in the BCL. We fill you up will all these and more on this week's show.
ENTRADAS PARA EL CHACHO Y EL REVERSO:https://www.gigantes.com/tienda/el-reverso-entrevista-sergio-rodriguez-evento/Objetivo cumplido para el Unicaja de Málaga y La Laguna Tenerife en la BCL al meterse en la Final Four tras pasar de cuartos de finalEl Unicaja de Málaga remató su serie de Playoffs contra el Pallacanestro Reggiana al ganar en tierras italianas por 82 a 72. Un 2-0 por la vía rápida para los de Ibon Navarro que les sirve para seguir adelante, evitarse de problemas y, encima, recuperar sensaciones a nivel interno.Más épica fue la victoria de La Laguna Tenerife que tuvo que emplearse a fondo para sellar su eliminatoria, también en Italia, estos contra el Derthona Basket por 77 a 64. Un partido en el que los de Txus Vidorreta tuvieron que sobrevivir en un mal día a nivel ofensivo y donde sacaron su mejor cara en el otro costado. Y como cada jueves os vamos a contar en Gigantes del Basket todo lo sucedido en la BCLEscucha este programa cada mañana en nuestro canal de YouTube o bien en plataformas de podcastGIGANTES DAILY es un programa de Gigantes Podcast en el que tendrás cada mañana la información que necesitas de NBA, Euroliga, ACB, FIBA, femenino y más.Dale a seguir y cada mañana, de lunes a viernes, tendrás un tema clave que va a marcar ese día en el mundo del baloncesto. Todo ello de la mano de Gigantes del Basket, el único medio profesional en España que lleva desde 1985 centrándose en exclusiva en el baloncesto. Más en Gigantes.com y nuestras redes socialesContacto: redaccion@gigantes.com
Recorded- April 7&11, 2025 Uploaded- April 12, 2025 Billy Horton joins the program to talk about last year in Yolo and the future in Marysville. Also a draft recap and a look at the past week in the BCL. And we finish the affiliated to independent review from last week along with a great promo from Grand Junction.
Featuring perspectives from Dr Nicole Lamanna and Dr Kerry Rogers, including the following topics: Introduction (0:00) Current Role of Covalent Bruton Tyrosine Kinase and Bcl-2 Inhibitors in Managing Chronic Lymphocytic Leukemia — Dr Lamanna (10:55) Novel Agents and Combination Strategies — Dr Rogers (31:21) CME information and select publications
TOYOTA限時優惠！即刻入主 RAV4, ALTIS,COROLLA SPORT,YARiS CROSS 免費升級JBL音響揚聲器，再享最高80萬零利率。打造車內頂級聽覺饗宴，買車就趁現在！ https://fstry.pse.is/7cy4sj —— 以上為 KKBOX 與 Firstory Podcast 廣告 —— 人家罷賽會被沒收比賽，但我們就算天打雷劈也是會繼續錄音。本週台籃有個令人振奮的消息，鋼鐵人終於拿下第二勝啦！擊敗的不是別人，正是聯盟龍頭aka台籃模範生桃園領航猿，到底他們施了什麼魔法，讓領航猿like a baby一樣，敗在他們手上？ 除了PLG，TPBL的卡位戰依舊激烈進行中，本以為雲豹前一週輸給戰神後要下去了，沒想到上週馬上討回來，屋漏偏逢連夜雨，戰神輸完雲豹還要再對上聯盟龍頭國王，毫無懸念吞下二連敗。目前戰神只領先雲豹1場，第三的海神更是和特攻只差0.5場，到底誰能搶到季後賽的最終席次，我們拭目以待。 聊完本週比賽，我們要跟大家隆重宣布，一年一度的台籃非官方獎項正式開跑啦，不管是哪個聯盟，哪支球隊，都都有參賽的資格，在開始投票前，我們預先討論了年度洋將和自創獎項：最佳副手獎，還沒想到投誰嗎？不妨收聽我們的節目，看看誰才是你心中最佳人選吧~ 成為
Featuring an interview with Ms Robin Klebig, including the following topics: Overview of the natural history and treatment landscapes of lymphoma subtypes (0:00) Structure and mechanisms of action of bispecific antibodies (23:41) Similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma (28:14) Case: A man in his early 50s with multiagent/multiregimen-refractory follicular lymphoma who experienced disease progression with chimeric antigen receptor T-cell therapy now receives mosunetuzumab (39:14) Case: A woman in her mid 60s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives glofitamab (49:08) Case: A man in his mid 60s with R/R high-grade B-cell lymphoma with MYC and Bcl-2 rearrangements receives epcoritamab (52:57) Case: A man in his early 60s with composite lymphoma receives epcoritamab (56:55) NCPD information and select publications
This is Episode 13 of Season 2 of The RUN TMC Podcast Dave and Duffy sit down with San Marin girls coach Tony Butler to unravel the 2025 changes in the NCS selection and seeding process and discuss his coaching journey and philosophy. Tony shares insights into building a strong team culture, his favorite drills, and adjustments in coaching strategy based on team and player dynamics. Dave and Duffy also serve up a small helping of local Marin basketball news and notes and provide an up to the hour update on the MCAL and BCL playoff pictures. Don't miss it, or you'll miss out. This interview occurred on February 2nd, 2025 Our next episode will air on or around February 12th Show Notes: Musical intro credit to Stroke 9//Logo credit to Katie Levine Content and opinions are those of Dave, Duffy and their guests and not of affiliated organizations or sponsors. email us at: theruntmcpodcast@gmail.com check out our website at: theruntmcpodcast.com Thank you to our sponsors: West End Nursery and Batiste Rhum and San Domenico Nike Summer Basketball Camps and The Hub in San Anselmo
CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-with-potentially-guideline-changing-implications-in-cllsll-and-mcl/32287/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-concordant-care-for-patients-with-cllsll-relapsing-after-2-prior-lines-of-therapy/32286/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-trial-evidence-that-drives-current-guidelines-for-patients-with-cllsll-and-mcl-receiving-third-line-therapies/32285/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-treatment-options-for-patients-with-cllsll-and-mcl-that-have-progressed-following-a-covalent-btk-inhibitor/32284/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
The Sports Rabbi Josh Halickman and Roy Jankelowitz from Israel Sportlooked back at all the State Cup action from Maccabi Tel Aviv getting knocked out as well as the domestic league play as well. We the spoke about the latest in Israeli basketball news from the BCL to the EuroCup and Euroleague.Make sure to subscribe to The Sports Rabbi Show on iTunes, Spotify or Google Podcasts.Also download our fabulous new App available for both Android and iPhone!Click here for the iPhone AppClick here for the Android App
Welcome to the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. John Allan from New York Presbyterian Hospital to discuss the latest highlights from ASH 2024, focusing on Chronic Lymphocytic Leukemia (CLL). We dived into three key studies: 1. SEQUOIA Update: Discover how this study led to the approval of Zanubrutinib in the frontline setting and its impressive progression-free survival rates compared to traditional chemotherapy. 2. AMPLIFY Study: Learn about the exciting combination of Acalabrutinib with Venetoclax and Obinutuzumab, and how it may pave the way for the first oral doublet/triplet combination approval in the U.S. 3. Ongoing Trials: We touch on the CELESTIAL TN-CLL trial and the promising combination of Zanubrutinib with Sonrotoclax, a new BCL-2 inhibitor. Additionally, we discuss the evolving role of CAR-T therapy in CLL, especially for patients who have progressed through multiple lines of treatment. Join us for an insightful discussion on the future of CLL treatment options, the importance of balancing efficacy and side effects, and the exciting developments in the field. Don't forget to check out our other ASH and SABCS 2024 discussions! Subscribe to stay updated on the latest in oncology research and treatments! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
In this week's episode, we'll be comparing BTK inhibitors in relapsed/refractory CLL. Then, we'll hear how researchers in the UK unraveled the genetic background of the AnWj blood group. Finally we'll learn about the role of BCL-2 and BAFF in CLL cell survival following venetoclax therapy. Featured Articles:Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotypeSustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINEVenetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia
Featuring perspectives from Dr Farrukh T Awan, Dr Bita Fakhri, Dr Kerry A Rogers and Dr William G Wierda, moderated by Dr Jeff Sharman, including the following topics: Introduction (0:00) Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD (1:44) Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors — Kerry A Rogers, MD (25:43) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Farrukh T Awan, MD (49:20) Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL — Bita Fakhri, MD, MPH (1:11:52) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — William G Wierda, MD, PhD (1:35:06) CME information and select publications
Recorded- December 13, 2024 Uploaded- December 14, 2024 In a slower week, we focus on the smaller things like Washington's new field, a return of the BCL, and a look at Diamond Baseball Holdings.
I'm so excited to have Dr. Bruce Lessey of ReceptivaDX join me on the podcast. Dr. Lessey has dedicated his research life to studying the lining of the uterus and more specifically, how to help embryos stick better. His research led to the discovery of the role of BCL-6 in the lining of the uterus as a diagnostic test patients can have done by their doctors to guide them toward the best protocol for transfer success. The test isn't for women just going through IVF either. This test can also be done to help women get an endometriosis diagnosis without going through a laparoscopy surgery. ⠀ ⠀ In addition to being a Fertility Doctor at The Fertility Center of the Carolinas, in Greenville SC, Dr. Lessey is also the scientific advisor for Cicero DX. His work on identifying BLC6 became the key component of the Receptivadx test. ⠀ ⠀ I'm delighted to have him on the show! Many IVF patients have benefited greatly from the Receptivadx test, and I'm looking forward to asking him a lot of questions about his work. Read the full show notes and transcript on Dr. Aimee's website Find out more about ReceptivaDX here: https://receptivadx.com/ Would you like to learn more about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, December 16th, 2024 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom. Subscribe to my YouTube channel for more fertility tips! Subscribe to the newsletter to get updates Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.
Recorded November 18, 2024. Trinity Long Room Hub Visiting Research Fellow Dr Shreya Atrey (Bonavero Institute of Human Rights, Oxford) in conversation with Prof Mark Bell (School of Law, TCD). Shreya Atrey is an Associate Professor in International Human Rights Law at the Faculty of Law, University of Oxford, and is based at the Bonavero Institute of Human Rights. She is an associate member of the Oxford Human Rights Hub, an Official Fellow and Racial Justice and Equality Fellow at Kellogg College, and a Senior Teaching Fellow at New College. Shreya is the Editor of the Human Rights Law Review (OUP). Previously, she was based at the University of Bristol Law School and has been a Max Weber Fellow at the European University Institute, Florence, and a Hauser Postdoctoral Global Fellow at the NYU School of Law, New York. She completed BCL with distinction and DPhil in Law on the Rhodes Scholarship from Magdalen College, University of Oxford. Shreya works on equality and human rights issues in comparative and international law. Her first monograph, Intersectional Discrimination (OUP 2019) won the runner-up Peter Birks Book Prize in 2020. Learn more at https://www.tcd.ie/trinitylongroomhub/
In Episode 2 of Season 2 of the Run TMC podcast, join hosts Duffy Ballard and Dave Levine on another deep dive into local basketball. In this episode, Dave sits down with Carly Amborn, an extraordinary basketball talent hailing from Marin County. Known affectionately as "The Prodigy" (or "Prod") by her peers, Carly shares her journey from playing CYO basketball against the boys, to competing in the MCAL and BCL with Archie Williams and San Domenico High Schools, to thriving in club basketball on the national stage with the elite Jason Kidd Select program, to securing a scholarship to play basketball at Stanford University in 2025. The interview with Carly was conducted on August 16th, 2024, after she made substantially more shots than Dave did in a shooting workout. Our next episode will drop on October 30th Show Notes: Musical intro credit to Stroke 9//Logo credit to Katie Levine Content and opinions are those of Dave, Duffy and their guests and not of affiliated organizations or sponsors. email us at: theruntmcpodcast@gmail.com check out our website at: theruntmcpodcast.com Thank you to our sponsors: Batiste Rhum and San Domenico Nike Summer Basketball Camps and The Hub in San Anselmo AI Summary Carly recounts her experiences growing up with a professional athlete as a parent and how it shaped her passion for basketball. Despite having multiple Division I offers, she explains why Stanford was always her dream school and delves into the recruiting process, including the differences between official and unofficial visits. Listeners will gain insight into Carly's club basketball experiences, where she played on the national stage for Jason Kidd Select, and how she handled the pressures of performing in front of top college coaches. Carly also discusses her participation in the U.S. National team tryouts and the invaluable lessons she learned from those high-stakes environments. Whether you're a young athlete aspiring to reach the next level or a fan of women's basketball, Carly's story of determination, resilience, and passion will inspire and motivate. Don't miss this captivating episode as we explore the making of a prodigy on and off the court.
In this week's episode I'm sharing with you 2 studies that came across my desk recently showcasing the importance of ruling out endometriosis if you've been told you have unexplained infertility. We go through this process with many of our Fertility Confidence Method clients, and advocating for testing when it comes to endometriosis has always been incredibly challenging. Today I'm sharing with you why this is important for those of you who have been struggling with unexplained infertility, recurrent implantation failure, or recurrent miscarriage and other ways we can potentially get answers when it comes to endometriosis that doesn't involve exploratory surgery. Topics Covered: Statistical rate of endometriosis in unexplained infertility Gold standard endometriosis diagnosis BCL-6 use in endometriosis diagnosis for unexplained infertility Study One: https://pubmed.ncbi.nlm.nih.gov/38943813/ Study Two: https://pubmed.ncbi.nlm.nih.gov/35642436/ Grab 20% off your first order of Needed supplements over at thisisneeded.com using the code DRKELSEY Fertility Confidence Bootcamp kicked off on Oct 7th, and there's still time to join us! Come build out your fertility care plan with me this week by registering at ttc.kelseyduncan.com/bootcamp
In today's episode, we're exploring a transformative concept championed by Keith McCurdy: the shift from raising children as consumers to nurturing them as contributors. In a world that often prioritizes “me first,” this mindset asks a different question: “How can I help?”But how does this philosophy play out in real life? The Classical School of Wichita put it to the test, and the results are inspiring. Their school culture has been transformed as students have taken ownership—not just of their learning, but of their entire community. From leading projects to supporting each other, these students have become active contributors.Join us as we delve into their journey with Classical School of Wichita teachers Grant Bickell and Evan Adams who share practical ways you can encourage your own children to become contributors, both at home and in school. This is an episode you won't want to miss—right here on BCL!Special Thanks to our sponsors!ZipCastWilson Hill AcademyAmericas Christian Credit UnionClassic Learning TestGordon CollegeClassical Academic PressLife Architects Coaching Stay tuned for more enlightening discussions on classical Christian education, and join us next time on BaseCamp Live! Remember to subscribe, leave us a review, and reach out to us at info@basecamplive.comDon't forget to visit basecamplive.com for more info and past episodes.
Have you ever noticed how asking the right question can spark incredible growth, deeper understanding, and engaging conversations? That's the dream of every teacher and parent, but it's not always easy! Jesus certainly knew the power of a well-placed question, often using them to challenge his listeners, provoke thought, and reveal deeper truths.Imagine using the same strategy to awaken meaningful conversations with your children, even in the back of the minivan on the ride home from school. So, what makes for a good and effective question, whether in the classroom or at a family meal?Our guest, Sarah Abbott, shares with us the Five Common Topics—a proven method to supercharge conversations both in the classroom and at home. Stay tuned for this episode of BCL as we learn how to ask the kind of questions that inspire and connect!We are thrilled to share the rollout of our new media platform, ZipCast, bridging communication between schools and parents and encouraging them on the go with what they need to know. Learn more about ZipCast at https://www.zipcast.media or reach out to us at hello@zipcast.media!Special thanks to this week's incredible sponsors:Americas Christian Credit UnionClassic Learning TestGutenberg CollegeClassical Academic PressLife Architects Coaching Stay tuned for more enlightening discussions on classical Christian education, and join us next time on BaseCamp Live! Remember to subscribe, leave us a review, and reach out to us at info@basecamplive.comDon't forget to visit basecamplive.com for more info and past episodes.
Imagine it's 1927, and you're flipping through a National Geographic magazine. On the back cover, a full-page ad invites you to join the Book of the Month Club, promising to send you a different great book each month. The tagline reads, “Relive the books that charmed you in your youth.”Fast forward 100 years, and what charmed most of us in our youth likely wasn't one of those great books that shaped Western thought and culture. Today, many Americans don't read regularly, and even fewer delve into the timeless classics that answer so many of life's basic questions.But it's never too late to start. Reading isn't just critical for our students; it's equally important for us as adults. So why not rediscover the joy of reading? Join us for this episode of BCL, where we explore the timeless value of great literature and how it can still enrich our lives today with special guest Cherie Harder, who has helped facilitate this for so many people.We are thrilled to share the rollout of our new media platform, ZipCast, bridging communication between schools and parents and encouraging them on the go with what they need to know. Learn more about ZipCast at https://www.zipcast.media or reach out to us at hello@zipcast.media!Special thanks to this week's incredible sponsors:Americas Christian Credit UnionClassic Learning TestGutenberg CollegeClassical Academic PressLife Architects Coaching Stay tuned for more enlightening discussions on classical Christian education, and join us next time on BaseCamp Live! Remember to subscribe, leave us a review, and reach out to us at info@basecamplive.comDon't forget to visit basecamplive.com for more info and past episodes.
Proverbs tells us that joy and laughter are good medicine for the soul, but the Bible also cautions us against foolish talk and crude joking. So what role should humor play in our classrooms, hallways, and homes? It is especially challenging when so much of what is presented to us today in the world is humor that is often inappropriate and at someone else's expense. Join us for this episode of BCL with Comedian Sean Hancock who helps us find joy and laughter in what is true, good and beautiful.Learn more about Sean Hancock's work and good, clean family humor at https://www.recycledmindscomedy.comSpecial Thanks to this week's sponsors:Americas Christian Credit UnionClassical Learning TestGrand Canyon UniversityGutenberg CollegeClassical Academic PressLife Architects Coaching Stay tuned for more enlightening discussions on classical Christian education, and join us next time on BaseCamp Live! Remember to subscribe, leave us a review, and reach out to us at info@basecamplive.comDon't forget to visit basecamplive.com for more info and past episodes.
Dr. John Sweetenham and Dr. Marc Braunstein look ahead at key abstracts across the spectrum of hematologic malignancies that will be presented at the 2024 ASCO Annual Meeting, including the OPTIC trial in chronic myeloid leukemia, treatment options for transplant-ineligible patients with multiple myeloma, and the 7-year analysis of the ECHELON-1 trial in classical Hodgkin lymphoma. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and the host of the ASCO Daily News Podcast. I'm delighted to be joined again this year by Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center in New York. We're going to be discussing some of the key abstracts in hematologic malignancies that will be featured at the 2024 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode, and disclosures of all guests on the podcast are available at asco.org/DNpod. Marc, it's great to have you back on the podcast. Dr. Marc Braunstein: It's a pleasure to be back, John. Dr. John Sweetenham: There are some exciting abstracts to be presented at this year's meeting, and I would like to begin, if we can, with Abstract 6501. As you know, this reports the four-year results from the OPTIC trial of ponatinib in patients with chronic-phase CML and the T315I mutation. Can you tell us about the trial and about these latest follow-up results? Dr. Marc Braunstein: Sure. Well, we've made tremendous progress in managing patients with CML in the past two decades using these oral tyrosine kinase inhibitors such as ponatinib. Ponatinib is a third-generation TKI that has activity in both Philadelphia-positive ALL as well as CML, and can overcome the resistance mutation you mentioned, called the T315I mutation, which is sometimes found following prior TKI therapy. The OPTIC study is a multicenter phase 2 randomized study of various doses of ponatinib in 283 chronic phase CML patients who had received 2 or more prior lines of therapy or those who had the presence of a T315I mutation, with the current analysis examining the major remission at 48 months, PFS, as well as OS. Of note, in this study, after patients have achieved a major remission with a transcript level of 1% or less, the study allowed for dose reduction of ponatinib from the original dose of either 45 milligrams or 30 milligrams to a reduced dose of 15 milligrams. So, when we look at the results, we find that the patients who had the highest overall response rates and higher rates of molecular remission were those who received the 45-milligram dose. And remember, these patients were allowed to be dose-reduced to the 15-milligram dose once they achieved a molecular remission of 1% or less. In addition, the rates of overall survival were highest in the 45-milligram dose as well. When looking at the T315I subgroup, the rates of molecular remission, the depth of remission, and the rates of progression-free survival, in general, were lower in that subgroup, but still higher in the 45-milligram dose than the 35- milligram dose. Furthermore, when looking at the rates of treatment-emergent adverse events leading to discontinuation, they were 8% in the 45-milligram dose compared to 14% in the 30-milligram dose and 5% in the patients who only received the 15-milligram dose. The authors have concluded that the 45-milligram dose, with the potential to be reduced to 15 milligrams after achieving 1% or less of the BCR-ABL transcript level, seems to be the right balance between efficacy and safety. Dr. John Sweetenham: Thanks, Marc. In the longer term, do you think that this study will, in any way, affect the position of ponatinib in the treatment algorithm for CML? Is it going to remain as a second or third-line option, or do you think there's any chance it will be moved up? Dr. Marc Braunstein: Well, that's a great question. There are other TKIs, such as asciminib, that also target the T315I mutation, and that mutation tends to develop after prior first-line or second-line TKI therapy. But given its activity in both ALL and CML, I think it's certainly reasonable to expect that ponatinib will be used in earlier lines of therapy given its efficacy in later lines. Dr. John Sweetenham: Let's change gears and move the focus to acute myeloid leukemia. There has been a lot of discussion around frailty in many different malignancies, but the impact of frailty on outcomes in AML is maybe something that hasn't been quite so well studied. In Abstract 6506, investigators did a population-based study in Ontario, Canada, that assessed the patient's frailty risk and the impact that might have on outcomes. What are your takeaways from this study, and how do you think these data will help optimize treatment decisions? Dr. Marc Braunstein: Yeah, I'm glad we're talking about this abstract John, because frailty scores are increasingly being used in hematologic malignancies to help guide goals and intensity of care. And as opposed to using age or performance status alone, these composite frailty assessment tools, such as the MFI tool that they used in this particular study, take into account multiple variables that are both physiologic, such as the patient's comorbidities, as well as social, and what kind of support system do they have, and things of that nature. And that accounts for their overall fitness. So, in this retrospective cohort study that was a population-based study in Ontario between 2006 and 2021, they looked at 5,450 patients retrospectively with acute leukemia and grouped those patients into 3 categories based on this frailty index. Patients who are either fit, somewhere in the middle between fit or frail, which they call pre-frail, or frail. And they looked at outcomes such as overall survival, comparing patients who got intensive chemotherapy regimens for induction or those who got non-intensive therapy for induction. Patients in either group could have been assigned to either fit, pre-frail, or frail although there are much more fit patients than those who got intensive induction. And so, looking at their findings, it was noted that patients who were in the frail category, not entirely unexpectedly, had lower overall survival when compared to those who were fit or pre-frail. I think the value of a study like this is not just to highlight the benefit of frailty scores to help predict which patients may ultimately have a shorter survival, but also to help potentially guide which patients may be more suitable for intensive versus less intensive induction. I will note that this study was conducted in an era where we didn't have the same sorts of less intensive induction that are very effective in less fit patients, such as the combination of azacytidine and venetoclax, which is commonly used in less fit patients nowadays. So, the study may encompass patients who didn't have access to that therapy because it wasn't available during that time. But I think it still, overall, does highlight the fact that assessing fitness or frailty in acute myeloid leukemia is important for predictive value. Dr. John Sweetenham: I agree. Marc, I don't know what your thoughts are on this, but it goes either way. I mean, I think that, if I remember the numbers correctly, 25% of fit patients received non-intensive therapy. So, is there a missed opportunity there for that group of patients who actually may have tolerated the intensive therapy but it was never offered? Dr. Marc Braunstein: That's an excellent point, John, and I think that highlights the importance of frailty indices because they take into account much more than one particular factor, or even just a subjective assessment of the patient in real time when they're first presenting. And they may have disease-specific features that are decreasing, say one element of their assessment such as their performance status. So, really taking these composite fitness scores into account may actually allow you to escalate therapy in a patient who may actually be fit but maybe perceived as less fit when they present. Dr. John Sweetenham: Yeah. So, I think, as you mentioned, there are better treatment options out there now maybe than there were at the time this study was conducted. Nevertheless, there may still be that opportunity for more intensive therapy for some of these patients when they are more holistically assessed. Let's move on and switch gears once again and talk about a study in multiple myeloma, the so-called IMROZ study, which is Abstract 7500. So, this is a study looking at treatment options for transplant-ineligible patients with newly diagnosed multiple myeloma. Some of these patients may not have a chance for subsequent therapy if they are not eligible for transplant. What are your thoughts on this study? Do you think we're closer to a new standard of care for patients who are not going to proceed to an autologous stem cell transplant? Dr. Marc Braunstein: It seems like every year there's a new standard of care for newly diagnosed multiple myeloma because there's so much data emerging, which is just wonderful. So, I think as background, at the 2023 ASH meeting, the IsKia study was presented, which is a randomized phase 3 study in newly diagnosed transplant-eligible patients. And that was using isatuximab with carfilzomib, lenalidomide, and dexamethasone upfront and that study did show a benefit in terms of reducing minimal residual disease compared to carfilzomib, lenalidomide, and dexamethasone alone. But that study was looking at fit newly diagnosed patients who were going on to stem cell transplant. Right now, the standard of care for patients who are not eligible for transplant is generally to use a 2 or 3-drug regimen, such as daratumumab, lenalidomide, and dexamethasone, based on the phase 3 MAYA study. But this study is really unique in that it looks at using a quadruplet regimen in patients who are transplant ineligible or not intended to go for transplant. So, the phase 3 IMROZ study was a randomized study of 446 patients that compared isatuximab, bortezomib, lenalidomide, and dexamethasone to bortezomib, lenalidomide, and dexamethasone alone. So, a quad versus a triplet regimen. The primary endpoint in this study was progression-free survival, but they also looked at secondary endpoints, such as complete response rate and minimal residual disease negativity. Just to quickly highlight the results and then discuss the standard of care, the median duration of treatment in this study was 53 months in the quad regimen and 31 months in the control arm. At a median follow-up of about 60 months, the progression-free survival was not reached with the quad regimen versus 54 months in the triplet, and that was a significant difference. In addition, the safety profile was pretty much consistent with the class, there were a bit more grade three or higher treatment-emergent adverse events with the ESA-containing regimen, 92% versus 84%, but no difference in adverse events leading to discontinuation in either arm. So, this study is certainly compelling in terms of using quadruplet-based regimens that contain an anti-CD38 monoclonal antibody for newly diagnosed patients who are not intended to undergo transplant. I think at the meeting, I will be interested to see the patient population that was included. Patients who are over the age of 80, for example, are excluded. So, I would like to know more about their fitness level and performance status. But I think it's clear, John, that using quad regimens over triplet regimens is just consistently superior in terms of efficacy outcomes. Dr. John Sweetenham: Right. I guess that, even though maybe we can't focus on the specific agents right now, it looks as if quad regimens are going to be the standard of care regimens for the future in this group. Do you think that is fair? Dr. Marc Braunstein: Very likely. Dr. John Sweetenham: Absolutely. Well, that's a pretty challenging group of patients. And so to move on again, let's talk about another, perhaps equally challenging group - patients with mantle cell lymphoma, particularly those who carry certain mutations. The so-called SYMPATICO study, which is reported in Abstract 7007, presents data on the efficacy and safety of ibrutinib and venetoclax in patients with mantle cell lymphoma who carry a TP53 mutation. We know that this mutation confers a high risk of early progressive disease and poorer outcomes when these patients are treated with standard chemoimmunotherapy for mantle cell. Trials to date have been limited to small single-arm studies. Can you tell us a little bit about this study and the outcomes and what you think it means for the future? Dr. Marc Braunstein: As a background, although BTK inhibitors such as ibrutinib have yet to be approved for newly diagnosed mantle cell lymphoma, acalabrutinib and zanubrutinib, which are second-generation BTK inhibitors, are FDA-approved for previously treated mantle cell lymphoma. Ibrutinib was withdrawn from the market. The lead author of this abstract, Dr. Michael Wang, had presented a late-breaking data from the phase 3 SYMPATICO trial at ASH last year, in which 267 patients with relapsed or refractory mantle cell lymphoma after one to five prior lines of therapy were randomized to receive the combination of ibrutinib plus the BCL-2 inhibitor venetoclax or ibrutinib plus placebo. That study showed there was a 32 versus 22-month progression-free survival with a hazard ratio of 0.65 at a median follow-up of 51 months, indicating the PFS benefit of the combination of ibrutinib and venetoclax compared to ibrutinib with placebo. So that leads us to this subgroup analysis in the current study being presented at ASCO, in which they looked at a subgroup of patients with mantle cell lymphoma who are at very high risk for treatment failure and early relapse - those are patients who have a mutation in TP53, which again is high risk for treatment failure. This abstract examined an open-label cohort of 44 first-line patients, as well as 75 patients who were in the relapse/refractory cohort, and compared to patients who either did or did not have the P53 mutation. When we look at the progression-free survival outcomes, the median progression-free survival in the first-line cohort of patients who did not have a P53 mutation was not reached, whereas those with the P53 mutation had a median progression-free survival of 22 months, which is still meaningful but still less than those who did not have a P53 mutation. Which again is not entirely unexpected. But the overall response rate of the combination of ibrutinib and venetoclax was very high at 90%, and the median duration of response was about 21 months. Now comparing this to the relapse/refractory cohort, in those without a P53 mutation, the progression-free survival of the combination of ibrutinib and venetoclax was about 47 months versus those who don't have the P53 mutation was about 21 months with an overall response rate of 80%. I think one takeaway looking at this comparison of the first-line and relapse/refractory setting is that patients seem to do very similar in terms of overall response rate and progression-free survival, whether they were in the first line or in the later lines of treatment if they had the P53 mutation, which says that the combination of ibrutinib and venetoclax is effective no matter which phase of the disease the patient might be in, indicating its overall activity and being strong. Dr. John Sweetenham: Yeah, I thought that was an interesting observation, actually, how similar the outcomes were in those two groups. Dr. Marc Braunstein: No, I agree. And I think although patients with TP53 mutations did comparatively worse than those without the mutation according to progression-free survival, overall response rate, or complete remission rates, they did seem to be similar whether a patient was in first-line or relapsed refractory if they were P53 mutant and were treated with this combination. So, I think we need further data in the first line, such as the data that's awaiting publication from the TRIANGLE study, which is examining upfront ibrutinib. But certainly, BTK inhibitors have significant activity in either the first line or the relapse setting of mantle cell lymphoma. Dr. John Sweetenham: Great. Thanks, Marc. Let's wind up with one more abstract, and this is Abstract 7053. It's a 7-year analysis of the so-called ECHELON-1 study. This was a study comparing the standard of care, ABVD, with the same regimen with bleomycin substituted by brentuximab vedotin for patients with previously untreated advanced-stage classical Hodgkin lymphoma. The study at the time it was originally reported, resulted in a significant practice change in the first-line therapy of Hodgkin's lymphoma. We now have mature follow-up. What are your take-homes from this study? Dr. Marc Braunstein: The ECHELON-1 study has certainly been a practice-changing clinical trial where, as you said, brentuximab with the backbone of AVD was compared to ABVD, which was the prior standard. And this was examined in newly diagnosed patients with classical Hodgkin lymphoma who were at advanced-stage, stage 3 or 4. The publication, first of the progression-free survival, and more recently, in the New England Journal of Medicine in 2022, where we saw the 6-year overall survival was 94% with the brentuximab-containing arm versus 89% in the control arm, established the brentuximab AVD, or otherwise called AAVD, as the standard of care in advanced stage newly diagnosed classical Hodgkin lymphoma. The current study is now reporting 7-year follow-up on about 1,300 randomized patients who were enrolled in this impressive study. Though at a median follow-up of 89 months now, the 7-year overall survival was quite similar, 94% versus 89%, again favoring the brentuximab-containing arm. In particular, this was driven by patients who had stage 4 disease or those patients who were aged less than 60 in subgroup analyses. So, what I take away from this abstract in the 7-year follow-up of the ECHELON-1 is that brentuximab with AVD remains the standard of care for previously untreated advanced-stage classical Hodgkin lymphoma. It is worth noting that the SWOG S1826 study that was presented at ASCO last year compared nivolumab with AVD compared to brentuximab AVD and did show a slight PFS advantage of 94% versus 86% with nivolumab AVD. Obviously, these were different studies with different patient populations enrolled, so we're really just cross-comparing different studies. But I think brentuximab AVD, given the survival benefit that is retained now at seven years in the current abstract, still remains the standard of care for advanced-stage classical Hodgkin lymphoma. The role of immune checkpoint inhibitors like nivolumab is making headway in terms of treating newly diagnosed patients as well. Dr. John Sweetenham: Yeah, thanks, Marc. I mean, one of the observations that I thought was of interest in this study was the outcome for patients who were PET-2 positive, when you compare AAVD and ABVD. It does seem as if even in those patients who are PET-2 positive, having had AAVD, they still apparently have a better outcome than those who received ABVD in that situation who were PET-2 positive. So, I think that's another interesting observation. I'm not quite sure what it means, except speaking to the overall superior efficacy of that regimen. Dr. Marc Braunstein: You make a great point, John, because it's worth noting that in ECHELON-1, a PET scan was done after cycle 2, but the study was not PET-adapted. So even if you had a positive PET, you continued for the full six cycles of treatment. But PET-2 status is often used in various studies of Hodgkin lymphoma to guide whether to give additional cycles or escalate therapy. So, I think the benefit of presenting those subgroups is that even if you were PET-2 positive, you still did better by continuing on the brentuximab-containing regimen. Dr. John Sweetenham: Yeah, exactly. I mean, the other important takeaway message, I think, is that the outcome for patients with advanced Hodgkin lymphoma seems to continue to steadily improve, which is great news and also really remarkable. And I'm excited to see there may be some additional data presented at one of the late-breaking abstracts in this year's meeting, so it will truly be interesting to see what that shows us as well. Dr. Marc Braunstein: Incredible. Dr. John Sweetenham: Well, Marc, as always, thank you for sharing your insights with us today on the ASCO Daily News Podcast. We look forward very much to hearing the updated data from these abstracts at the meeting. Dr. Marc Braunstein: As do I and thank you so much for inviting me again. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's guest: Dr. Marc Braunstein @docbraunstein Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness Dr. Marc Braunstein: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp Speakers' Bureau: Janssen Oncology Research Funding (Institution): Janssen, Celgene/BMS
St. Augustine famously remarked that “to sing is to pray twice.” Music and arts play vital roles in our daily lives and are essential components of any classical Christian school or home. However, engaging meaningfully with traditional forms of music, as well as with worship through prayer and Scripture, can be challenging—especially if we don't have good examples around us as adults and the idea of leading something we aren't very good at can be intimidating. My guest today has done us a favor as schools and parents with a fresh vision and proven and practical ways to engage well in music and the arts in our homes and schools.Special Thanks to this week's incredible sponsors:Americas Christian Credit UnionClassical Learning TestGrand Canyon UniversityGutenberg CollegeLife Architects CoachingOrder Cantate Domino by Dr. Preston Atwood at https://hymnworks.com/product/cantate/. You can also find the Spiral-bound option for instrumentalists at https://hymnworks.com/product/cantate-spiral/ Stay tuned for more enlightening discussions on classical Christian education, and join us next time on BaseCamp Live! Remember to subscribe, leave us a review, and reach out to us at info@basecamplive.comDon't forget to visit basecamplive.com for more info and past episodes.
© 2020-2025 Ivy Podcast Discovery LLC
